ArticleFrontiers in medicine2025
The inflammatory index and cytokines are associated with non-alcoholic fatty liver disease in type 2 diabetes mellitus.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mechanistic Investigation of Astragalus Root in the Management of T2DM-NAFLD Comorbidity: An Integrated Network Pharmacology, Molecular Docking, Molecular Dynamics Simulation, and In Vitro Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Triglyceride-glucose related index and its association with coronary heart disease risk in patients with metabolic dysfunction-associated steatotic liver disease: a retrospective analysis based on type 2 diabetes mellitus.Frontiers in endocrinology · 2026Article
- Systemic immuno-metabolic inflammatory indices (neutrophil-to-HDL cholesterol ratio and systemic inflammation response index) are strongly associated with metabolic dysfunction-associated steatotic liver disease: a propensity score-matched study.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD), which is characterized by hepatic steatosis in the absence of excessive alcohol consumption, is now increasingly recognized as a significant crucial factor contributing to chronic diseases, including diabetes. Moreover, it may progress to advanced hepatic pathologies such as fibrosis, cirrhosis, and even liver cancer. Systemic inflammation could be a potential mediator in the pathogenesis of diabetes secondary to NAFLD. Thus, we aim to evaluate inflammatory biomarkers to delineate their prognostic utility. Methods: A retrospective analysis was conducted on the clinical data of 624 participants from Tianjin Third Central Hospital, spanning from January 2023 to December 2024. Among them, 234 patients with NAFLD and type 2 diabetes mellitus (T2DM) were enrolled as NAFLD + T2DM group, 197 patients with T2DM were included in T2DM group and 193 healthy individuals were recruited into the control group. Independent t-tests or Mann-Whitney U tests were employed to compare demographic and biochemical parameters. Correlation analysis was carried out to assessed the association between NAFLD-T2DM comorbidity and systemic inflammation. The receiver operating characteristic curve (ROC) analysis was utilized to identify the optimal predictor and the optimum cut-off value for the comorbidity of NAFLD- and T2DM. Results: Among serum cytokines, laboratory indicators, and six indexes, TyG, MHR, NHR, NLR and IL-6 presented a significant positive correlation with the incidence in participants with NAFLD and T2DM. Additionally, NLR (AUC: 0.868) and IL-6 (AUC: 0.777) performed the best among inflammatory indicators and cytokines. The predictors obtained from the combined testing of NLR, IL-6, and TyG offer a superior predictive value for the identification and management of NAFLD in T2DM patients. Conclusion: Based on the findings, the predictors obtained from the combined testing of NLR, IL-6, and TyG emerge as the most practical and readily accessible indicators for early screening of NAFLD from patients with T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.